Die meistzitierten Artikel
|
Rang |
Autoren |
Paper |
Zitierungen |
1. | Ettinger B, ..., Glüer CC, ..., Cummings SR (Group Multiple Outcomes Raloxifene Evaluation) | Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene - Results from a 3-year randomized clinical trial JAMA-J. AM. MED. ASSOC. 282 (7): 637-645 AUG 18 1999 | 686 |
2. | Schilling AF, Beil FT, Shen JH, Vinson C, Rueger JM, Karsenty G | Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. CELL 100 (2): 197-207 JAN 21 2000 | 264 |
3. | Eastell R (Group Vertebral Efficacy Risedronate) | Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. OSTEOPOROSIS INTERNATIONAL 11 (1): 83-91 2000 | 256 |
4. | McClung MR, ..., Zippel H, ..., Chestnut CH (Group Hip Intervention Program Study Grp) | Effect of risedronate on the risk of hip fracture in elderly women. NEW ENGLAND JOURNAL OF MEDICINE 344 (5): 333-340 FEB 1 2001 | 245 |
5. | Orwoll E, ..., Pietschmann P, ..., Felsenberg D, ...Valeriano J | Alendronate for the treatment of osteoporosis in men. NEW ENGLAND JOURNAL OF MEDICINE 343 (9): 604-610 AUG 31 2000 | 174 |
6. | Ducy P, ..., Priemel M, ..., Amling M, Karsenty G | A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. GENES & DEVELOPMENT 13 (8): 1025-1036 APR 15 1999 | 161 |
7. | Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H | HMG-CoA reductase inhibitors and the risk of fractures JAMA-J. AM. MED. ASSOC. 283 (24): 3205-3210 JUN 28 2000 | 153 |
8. | Gong YQ, ..., Zabel B, ..., Warman ML (Group Osteoporosis Pseudoglioma Syndrome) | LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. CELL 107 (4): 513-523 NOV 16 2001 | 143 |
9. | Pols HAP, Felsenberg D, ..., Stych B (Group Fosamax Int Trial Study Grp) | Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study. OSTEOPOROSIS INT. 9 (5): 461-468 1999 | 136 |
10. | Talts JF, Andac Z, Göhring W, Brancaccio A, Timpl R | Binding of the G domains of laminin alpha 1 and alpha 2 chains and perlecan to heparin, sulfatides, alpha-dystroglycan and several extracellular matrix proteins. EMBO JOURNAL 18 (4): 863-870 FEB 15 1999 | 132 |